Hotsko M. J., Serhiyenko V. O., Bobrovych I. V., Makarovska R. J., Serhiyenko O. O.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Aim. Our study was aimed to evaluate the safety and efficiency of the herbal drug “Tireoclean” among patients with chronic autoimmune thyroiditis (AIT). Object and methods. 60 patients with AIT were involved into the study. The mean age of the patients was 40.57 ± 1.65 years, body mass index 26.07±0.48 kg/m2 , disease duration 2.97 ± 0.38 years. The diagnosis of AIT was verified in the presence of at least two major disease criteria. Patients were divided into two groups: control (n=30) and treatment (n=30). To patients from treatment group was prescribed “Tireoclean” 1 capsule two times daily. The duration of the treatment was 3 months. The examination plan included determination of thyroid-stimulating hormone (TSH), free thyroxine (FT4), anti-thyroid peroxidase antibodies (TPO) and anti-thyroglobulin antibody (ATG) using the enzyme-linked immunosorbent assay (Diagnostic Systems of Ukraine) using the HumareaderPlus analyzer (Human, Germany). All patients underwent thyroid ultrasound on the Philips HD11XE device (Austria) in dynamics. Results. According to the obtained data, it was found that the prescription of “Tireoclean” as a part of complex therapy of patients with AIT, was associated with the positive dynamics in the field of somatic disorders. By evaluation of thyroid status, no statistically significant changes in TSH and FT4 concentrations were found (p > 0.05). However, when performing this analysis in the subgroup with subcompensated hypothyroidism, a significant decrease in TSH (5.88 ± 0.56 µU/mL before treatment vs 4.49 ± 0.38 µU/mL after treatment, p < 0.05) and an increase in FT4 (1.09 ± 0.11 pg/mL before treatment vs 1.21 ± 0.11 pg/mL after treatment, p < 0.05) after “Tireoclean” prescription was found. By assessing the dynamics of the ultrasound parameters of the thyroid gland, no significant changes in the total volume of the gland were detected (13.51 ± 1.42 cm3 before treatment vs 13.32 ± 1.25 cm3 after treatment). We probably did not record any sonographic changes since most patients were included in the study with baseline normal or reduced thyroid volume. In the control group, no statistically significant changes were detected (p > 0.05). An analysis of the tolerability and clinical safety of “Tireoclean” in addition to standard therapy shows that in 100% of cases the therapy was characterized by good tolerability and safety. Conclusions. Prescription of “Tireoclean” to patients with AIT, in addition to standard therapy, allows to reduce somatic disorders, to normalize the functional state of thyroid gland, accompanied by the decrease in the levels of TPO and ATG. Administration of “Tireoclean” is characterized by good tolerability and safety. Obtained results could witness the feasibility of “Tireoclean” inclusion to the complex treatment of patients with chronic autoimmune thyroiditis.

chronic autoimmune thyroiditis, Potentilla alba L., Aronia melanocarpa, Crataegus sanguinea Pall., treatment.

1. Kravchenko VI. Yodnyy deftsyt yak prychyna vysokoyi rozpovsyudzhenosti tyreoyidnoyi patolohiyi sered naselennya rehioniv, shcho postrazhdaly pislya avariyi na CHAES. Zhurnal NAMN Ukrayiny. 2016;22(2):222-9. [in Ukrainian].
2. Boehm BO, Steinert M, Dietrich JW, Peter RU, Belyi D, Wagemaker G, et al. Thyroid examination in highly radiation exposed workers after the Chernobyl accident. Eur J Endocrinol. 2009;160(4):625-30.
3. Agate L, Mariotti S, Elisei R, Mossa P, Pacini F, Molinaro E, et al. Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiationinduced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. J Clin Endocrinol Metab. 2008;93(7):2729-36.
4. Larin OS, Pankiv VI, Selivanenko MI, Hrachova OO. Analiz diyalʹnosti endokrynolohichnoyi sluzhby Ukrayiny u 2010 rotsi ta perspektyvy rozvytku medychnoyi dopomohy khvorym z endokrynnoyu patolohiyeyu. Mizhnarodnyy endokrynolohichnyy zhurnal. 2011;3(35):10-8. [in Ukrainian].
5. Kvachenyuk AN, Kvachenyuk YeL. Ispol’zovaniye fitoterapii pri lechenii zabolevaniy shchitovidnoy zhelezy. Vrachebnoye delo. 2012;3(4):108- 15. [in Russiаn].
6. Kaminskiy AV, Kiseleva IA, Teplaya YeV. Klinicheskiye vozmozhnosti primeneniya lapchatki beloy v profilaktike i lechenii bol’nykh s patologiyey shchitovidnoy zhelezy. Vrachebnoye delo. 2013;8:99-108. [in Russiаn].
7. Tkachenko VI, Maksymetsʹ YaA, Vydyboretsʹ NV, Kovalenko OF. Analiz poshyrenosti tyreoyidnoyi patolohiyi ta zakhvoryuvanosti na neyi sered naselennya Kyyivsʹkoyi oblasti ta Ukrayiny za 2007–2017 rr. Mizhnarodnyy endokrynolohichnyy zhurnal. 2018;14(3):279-84. [in Ukrainian].
8. Chekalina NI, Kazakov YuM, Petrov YeYe. Suchasni uyavlennya pro avtoimunnyy tyreoyidyt: etiolohiya ta patohenez. Aktualʹni problemy suchasnoyi medytsyny. 2012;12(4):229-32. [in Ukrainian].
9. Oliynyk VA. Khronichnyy limfotsytarnyy tyroyidyt (tyreoyidyt Khashymoto): suchasnyy stan problemy. Endokrynolohiya. 2006;11(1):71-9. [in Ukrainian].
10. Rymar OD, Mikitinskaya AK, Maksimov VN. Rol’ geneticheskikh faktorov v etiologii autoimmunnykh zabolevaniy shchitovidnoy zhelezy. Sibirskiy meditsinskiy zhurnal. 2011;26(4):34-41. [in Russiаn].
11. Kaminsʹkyy OV. Standarty nadannya medychnoyi dopomohy khvorym z patolohichnymy stanamy shchytopodibnoyi zalozy v umovakh diyi nehatyvnykh chynnykiv dovkillya. 2-e vydannya. Kyyiv: Start-98; 223 s. [in Ukrainian].
12. Zimmermann VB, Khrle J. The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. Thyroid. 2002;12:867-78.
13. Rustembekova SA, Ametov AS, Tliashinova AM. Elementarnyy disbalans pri patologii shchitovidnoy zhelezy. RMZH: Endokrinologiya. 2008;16:1078. [in Russiаn].
14. Laurberg P, Bülow Pedersen I, Knudsen N, Ovesen L, Andersen S. Environmental iodine intake affects the type of nonmalignant thyroid disease. Thyroid. 2001;11:457-69.
15. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev. 1994;15(6):788-830.
16. Mamenko MYe, Yerokhina ОI, Holovchenko NM. Profilaktyka ta likuvannya endemichnoho zoba v rehionakh iz vysokoyu poshyrenistyu poyednanoho defitsytu yodu ta zaliza. Ukrayinsʹkyy medychnyy alʹmanakh. 2008;11(5):101-4. [in Ukrainian].
17. Hess SY, Zimmermann MB, Arnold M, Langhans W, Hurrell RF. Iron deficiency anemia reduces thyroid peroxidase activity in rats. J Nutr. 2002;132(7):1951-5.
18. Shimanovskiy NL, Rogovskiy VS. Perspektivy primeneniya preparatov kvertsetina dlya profilaktiki i lecheniya ateroskleroza. Prirodnaya meditsina. 2013;2(14):66-9. [in Russiаn].
19. Kiseleva IA, Teplaya YeV, Kaminskiy AB. Primeneniye rastitel’nogo preparata «Al’ba® » v lechenii bol’nykh s patologiyey shchitovidnoy zhelezy. Vrachebnoye delo. 2012;8:116-9. [in Russiаn].
20. Panʹkiv BI. Vykorystannya fitoterapiyi v kompleksnomu likuvanni khvorykh na dyfuznyy toksychnyy zob. Mizhnarodnyy endokrynolohichnyy zhurnal. 2012;42:114-7. [in Ukrainian].
21. Pan’kiv VI, Gur’yanov VG, Petrovskaya LR. Dinamika razmerov shchitovidnoy zhelezy u bol’nykh diffuznym i uzlovym zobom, autoimmunnym tireoiditom na fone monoterapii preparatom Al’ba® v razlichnykh regionakh Ukrainy. Mezhdunarodnyy endokrinologicheskiy zhurnal. 2017;13(8):526-35. [in Russiаn].
22. Voloshyn OI, Vasyuk VL, Malkovych NM, Senyuk BP. Osnovy fitoterapiyi ta homeopatiyi. Vyzhnytsya: Cheremosh; 2011. 256 s. [in Ukrainian].
23. Barna OM. Perspektyvy vykorystannya aroniyi chornoplidnoyi v medychniy i farmatsevtychniy praktytsi. Fitoterapiya. Chasopys. 2013;3:49- 51. [in Ukrainian].
24. Lupascu N, Cadar E, Cherim M, Erimia CL, Sibru R. Research concerning the efficiency of Aronia Melanocarpa for pharmaceutical purpose. Eur J Interdiscip Stud. 2016;4(1):115-269.
25. Kumar D, Arya V, Bhat ZA, Khan NA, Prasad DN. The genus Crataegus: chemical and pharmacological perspectives. Rev Bras Farmacogn. 2012;22(5):1187-200.

«Bulletin of problems biology and medicine» Issue 4 Part 2 (154), 2019 year, 83-87 pages, index UDK 616.441-002.28-085.322:582.734

10.29254/2077-4214-2019-4-2-154-83-87